Related references
Note: Only part of the references are listed.Site-specific antibody drug conjugates for cancer therapy
Siler Panowski et al.
MABS (2014)
HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design
Bart E. C. G. de Goeij et al.
MABS (2014)
Antibodies to watch in 2014 Mid-year update
Janice M. Reichert
MABS (2014)
Epidermal growth factor receptor targeting in cancer: A review of trends and strategies
Chetan Yewale et al.
BIOMATERIALS (2013)
Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo
D. Hristodorov et al.
BRITISH JOURNAL OF CANCER (2013)
Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy
Vidyalakshmi Chandramohan et al.
CLINICAL CANCER RESEARCH (2013)
SNAP-tag based Agents for Preclinical In Vitro Imaging in Malignant Diseases
Manal Amoury et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Multimerization of anti-(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers
Ryutaro Asano et al.
FEBS JOURNAL (2013)
Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies
Itay Barnea et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2013)
Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu
Yu Cao et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Modified Trastuzumab and Cetuximab Mediate Efficient Toxin Delivery While Retaining Antibody-Dependent Cell-Mediated Cytotoxicity in Target Cells
Roger Gilabert-Oriol et al.
MOLECULAR PHARMACEUTICS (2013)
The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
Hans-Peter Gerber et al.
NATURAL PRODUCT REPORTS (2013)
Antibody Therapeutics in Cancer
Mark X. Sliwkowski et al.
SCIENCE (2013)
Immunotoxins: The Role of the Toxin
Antonella Antignani et al.
TOXINS (2013)
The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment
Takamitsu Sasaki et al.
BIOMED RESEARCH INTERNATIONAL (2013)
A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
Vidyalakshmi Chandramohan et al.
ONCOIMMUNOLOGY (2013)
Species-Dependent Functionality of the Human Cytolytic Fusion Proteins Granzyme B-H22(scFv) and H22(scFv)-Angiogenin in Macrophages
Sonja Schiffer et al.
ANTIBODIES (2013)
Targeting the ERBB family in cancer: couples therapy
Niall Tebbutt et al.
NATURE REVIEWS CANCER (2013)
In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
Philippe P. Monnier et al.
ANTIBODIES (2013)
In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor
Maria Leonor Alvarenga et al.
ANALYTICAL BIOCHEMISTRY (2012)
Plasmonic nanobubble-enhanced endosomal escape processes for selective and guided intracellular delivery of chemotherapy to drug-resistant cancer cells
Ekaterina Y. Lukianova-Hleb et al.
BIOMATERIALS (2012)
In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model
Alessa Pardo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
scFv Antibody: Principles and Clinical Application
Zuhaida Asra Ahmad et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)
Richard Cathomas et al.
CLINICAL CANCER RESEARCH (2012)
Therapeutic targets and recent advances in protein immunotoxins
J. Madhumathi et al.
CURRENT OPINION IN MICROBIOLOGY (2012)
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
Lisa A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab
Mareike Voigt et al.
NEOPLASIA (2012)
Antibody-Based Immunotoxins for the Treatment of Cancer
Nurit Becker et al.
ANTIBODIES (2012)
SNAP-Tag Technology Mediates Site Specific Conjugation of Antibody Fragments with a Photosensitizer and Improves Target Specific Phototoxicity in Tumor Cells
Ahmad Fawzi Hussain et al.
BIOCONJUGATE CHEMISTRY (2011)
Panitumumab in Combination with FEC 100 (5-Fluorouracile, Epirubicin, Cyclophosphamide) Followed by Docetaxel (T) in Patients with Operable, Triple Negative Breast Cancer (TNBC): Final Results of a Multicentre Neoadjuvant Pilot Phase II Study.
J-M Nabholtz et al.
CANCER RESEARCH (2011)
One target, different effects: a comparison of distinct therapeutic antibodies against the same targets
Hyunbo Shim
EXPERIMENTAL AND MOLECULAR MEDICINE (2011)
A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer
John E. Weldon et al.
FEBS JOURNAL (2011)
Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor
Klaus Koefoed et al.
MABS (2011)
Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells
Christoph Stein et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
Mikkel Wandahl Pedersen et al.
CANCER RESEARCH (2010)
Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein
Florian Kampmeier et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy
Gur Pines et al.
FEBS LETTERS (2010)
Epidermal growth factor receptor expression affects the efficacy of the combined application of saponin and a targeted toxin on human cervical carcinoma cells
Diana Bachran et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Site-Specific, Covalent Labeling of Recombinant Antibody Fragments via Fusion to an Engineered Version of 6-O-Alkylguanine DNA Alkyltransferase
Florian Kampmeier et al.
BIOCONJUGATE CHEMISTRY (2009)
Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin
Jeannick Cizeau et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425
Vishal Kamat et al.
CANCER BIOLOGY & THERAPY (2008)
Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin
Thomas Nachreiner et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes
Bettina Stahnke et al.
MOLECULAR CANCER THERAPEUTICS (2008)
A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells
Michael Schwenkert et al.
MELANOMA RESEARCH (2008)
Expression of receptor tyrosine kinases and apoptotic molecules in rhabdornyosarcoma - Correlation with overall survival in 105 patients
Paul M. Armistead et al.
CANCER (2007)
Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors
Ravibhushan Singh et al.
MOLECULAR CANCER THERAPEUTICS (2007)
A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells
P. Wolf et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma
Ramapriya Ganti et al.
MODERN PATHOLOGY (2006)
Development of antibodies for cancer therapy
D. K. Wilkins et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2006)
EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells
Christoph Mamot et al.
JOURNAL OF DRUG TARGETING (2006)
Antibody targeted drugs as cancer therapeutics
D Schrama et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Immunotoxins for targeted cancer therapy
Robert J. Kreitman
AAPS JOURNAL (2006)
Delivery into cells: lessons learned from plant and bacterial toxins
K Sandvig et al.
GENE THERAPY (2005)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
G von Minckwitz et al.
BREAST CANCER RESEARCH (2005)
Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells
M Stöcker et al.
PROTEIN EXPRESSION AND PURIFICATION (2003)
Clonal analysis of a human antimouse antibody (HAMA) response
SJ Thorpe et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2003)
Ligand-targeted therapeutics in anticancer therapy
TM Allen
NATURE REVIEWS CANCER (2002)
Share Paper
